The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Leyden Labs Secures $70 Million Funding and Acquires CoV Biotechnology for Advancing Intranasal Antibody Programs
Jan 12, 2025•over 1 year ago
Contract Type
partnership
LeidenBiotechnologyresearch
Description
Leyden Laboratories has raised $70 million in funding to advance its Mucosal Protection Platform and has acquired CoV Biotechnology. The funding will support the initiation of human efficacy studies of PanFlu, advancements in the company’s Mucosal Protection Platform research, and other pipeline activities. The company's approach leverages broadly protective intranasally administered antibodies to protect against influenza and coronaviruses.
Company Information
Company
Leyden Labs
Location
Emmy Noetherweg
Leiden, South Holland, Netherlands
About
Leyden Labs aims to help people live their lives to the fullest. Our platform targets commonalities of viral families to protect humanity from known and future viruses. Our portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many variants of respiratory viruses, including ones in the influenza and coronavirus families.
The Leyden Labs’ energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.
LeidenBiotechnologyresearch